Many new treatments for metastatic breast cancer are under study. Most of these are drug therapies.
A clinical trial offers you the chance to try a new treatment and possibly benefit from it. Learning a new drug is better than standard treatment can also help others.
Findings from clinical trials determine whether or not new treatments will become a part of the standard of care for metastatic breast cancer. Some treatments may even go on to be used to treat early stage breast cancer.
Some clinical trials compare a new treatment to the standard of care. So, not everyone in the trial gets the new treatment. However, even those who don’t get the new treatment still get the standard treatment, just as they would if they didn’t join the trial.
Talk with your oncologist about clinical trials. Remember, like all aspects of cancer care, the decision to join a clinical trial is a personal one.
Learn more about clinical trials, including how to enroll and the informed consent process.
Find a list of questions to ask your doctor about clinical trials.
If you've been diagnosed with metastatic breast cancer, consider joining a clinical trial when your health care provider is considering changing treatments or before starting a new treatment.
Placebos aren’t used in metastatic breast cancer clinical trials. You will get either the new treatment or the standard treatment.
If your medical center doesn't offer clinical trials, you may want to get a referral from your oncologist to a cancer center that does.
BreastCancerTrials.org in collaboration with Susan G. Komen® offers a custom matching service to help you find clinical trials for people with metastatic breast cancer.
Susan G. Komen® Breast Cancer Clinical Trial Information Helpline
If you or a loved one needs information or resources about clinical trials, call our Clinical Trial Information Helpline at 1-877 GO KOMEN (1-877- 465- 6636) or email firstname.lastname@example.org.
The helpline offers breast cancer clinical trial education and support, such as:
What is Susan G. Komen® doing?
Susan G. Komen® is one of several organizations that supported the Reagan-Udall Foundation and the Food and Drug Administration (FDA) in the development of the Expanded Access Navigator website.
Expanded Access (EA) is also known as “compassionate use.” It gives patients access to drugs before they have FDA approval. This may be needed when patients have exhausted their treatment options and who are not eligible for (or unable to participate in) a clinical trial.
The Expanded Access (EA) Navigator tool serves as a clearinghouse of information and resources to help patients and their doctors more easily access information that could impact treatment decisions. The EA Navigator explains what EA is, who may be eligible, how the request process works and the regulatory and policy issues around EA.
The EA Navigator also contains the pharmaceutical companies EA policies. The open EA programs are listed on the National Institutes of Health’s clinical trials website, www.clinicaltrials.gov.
Metastatic Breast Cancer
Research Fast Facts
Facts for Life: Metastatic Breast Cancer
Breast Cancer Clinical Trial Information Helpline
Metastatic Breast Cancer Progress
Patient Perspective on Clinical Trials
1-877 GO KOMEN(1-877-465-6636)